AbbVie

AbbVie

Organization

Heard in 50 episodes across 17 shows since Oct 2025

AbbVie Inc. is a publicly traded American biopharmaceutical company headquartered in North Chicago, Illinois, spun off from Abbott Laboratories in 2013. It researches, develops, manufactures, and commercializes medicines across areas including immunology, oncology, neuroscience/CNS, aesthetics, and other specialty-care fields; the podcast discussions primarily reference its partnerships, business-development activity, CNS pipeline, and exposure to pharmaceutical patent expirations.

Discussed inMarkets95%Business5%

Episodes

50
across 17 shows

This week

0
episodes on 0 shows

Expert statements

14
12 positive · 2 negative

Share of the conversation

Mentions of AbbVie per 1,000 mentions of anything, 7-day rolling, across the podcasts PodLume Trends follows.

0.0‰0.03‰0.05‰0.07‰0.1‰Aug 24Sep 15Oct 8Oct 30Nov 21
Show the data
DayShare (7-day)Mentions
Aug 260.01‰1
Sep 280.01‰1
Oct 50.02‰2
Oct 60.03‰1
Oct 70.04‰2
Oct 90.06‰2
Oct 130.06‰3
Oct 160.05‰3
Oct 190.06‰1
Oct 220.05‰2
Oct 260.02‰1
Oct 270.03‰1
Oct 300.03‰2
Nov 40.03‰2
Nov 50.04‰1
Nov 90.07‰6
Nov 110.07‰2
Nov 130.08‰2
Nov 160.04‰1
Nov 170.05‰1
Nov 200.02‰1

The full trend: rank, tone and why it is trending →

Email alert

Email me when AbbVie comes up on a podcast

One email a week at most, with the new episodes that mention AbbVie. Free, no account needed, unsubscribe in one click.

What experts have said about AbbVie

14 statements · 12 positive · 2 negative

  1. Jim LabenthalPositiveNov 11, 2026· Halftime Report

    AbbVie has delivered twice the market return with one-third the market risk.

    “You're getting twice the market return for one-third of the market risk.”

    Listen at 30:46

    Open the episode · AI Relief Rally, Nvidia Governance and CoreWeave Earnings
  2. Jared HolzPositiveOct 22, 2026· CNBC's "Fast Money"

    Investors should wait to buy AbbVie at a lower price.

    “I would just love to buy it cheaper.”

    Listen at 31:28

    Open the episode · Tech Tumbles In Market Sell-Off… And Moderna’s Meltdown After Data Leak 10/22/26
  3. Chef StationPositiveOct 16, 2026· Biotech Bulls & Breakthroughs

    Aldeyra’s potential AbbVie partnership would have approximately 60–40 economics.

    “it would also allow them to go into a partnership where it's pretty much 60-40 AbbVie.”

    Listen at 15:09

    Open the episode · Biotech Stocks to Watch: FDA Shakeups, ESMO Data & Late 2026 Biotech Catalysts Sheff Is Watching

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Episodes

50 episodes featuring AbbVie, newest first